Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endometrin vs Activella for Endometrial Protection in Menopausal Women
NCT00919919Phase 2Unknown
- Sponsor
- Rabin Medical Center
- Start
- Jun 2009
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of progesterone in endometrial hyperplasia (EH) and endometrial cancer (EC) (2 arms), sponsored by Rabin Medical Center. Primary endpoint: Proportion of women with endometrial thickness not exceeding 8mm and change not exceeding 3mm at 1 year. Status: unknown.
02
Drugs
progesterone
03
Conditions
endometrial hyperplasia (EH)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT00919919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00919919.